A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis

Ogata, H.; Matsui, T.; Nakamura, M.; Lida, M.; Takazoe, M.; Suzuki, Y.; Hibi, T.
September 2006
Gut;Sep2006, Vol. 55 Issue 9, p1255
Academic Journal
Background and aims: Immunosuppressive therapy with intravenous ciclosporin is an alternative treatment option to total colectomy for patients with ulcerative colitis (UC), while the benefits of oral administration of tacrolimus are not well defined and are based on reports of several uncontrolled studies. Methods: Patients with refractory active UC were randomly assigned to a high trough concentration (10-15 ng/ml) group (HI group) (n = 21), low trough concentration (5-10 ng/ml) group (LI group) (n = 22), or placebo group (n = 20). Patients received an initial oral dose of 0.05 mg/kg tacrolimus or placebo twice daily. Efficacy was evaluated in 60 patients based on a disease activity index (DAI) score. Fifty eight patients had additional treatment with tacrolimus and were evaluated for efficacy in a 10 week open label extension. Results: An improvement in DAI score (≥4 points, all categories improved) was observed for 68.4% of cases in the HI group compared with 10.0% in the placebo group (p<0.001). In the HI group, 20.0% of patients had clinical remission and 78.9% had mucosal healing. In the open label extension, 55.2% of all patients had an improved DAI score at week 10. Mean dose of prednisolone was reduced from 19.7 mg/day at study entry to 7.8 mg/day at week 10. The incidence of side effects in the HI group was significantly higher than that of the placebo group (p=0.043). The most common event was mild finger tremor. Conclusions: Our findings demonstrate dose dependent efficacy and safety of oral tacrolimus for remission-induction therapy of refractory UC. The optimal target range appears to be 10-15 ng/ml in terms of efficacy with two week therapy.


Related Articles

  • Steroid-Refractory Severe Ulcerative Colitis. Moss, Alan C.; Peppercorn, Mark A. // Drugs;2008, Vol. 68 Issue 9, p1157 

    Approximately 15% of patients with ulcerative colitis will experience a severe episode requiring hospitalization. Although intravenous corticosteroids are the current first-line therapy for these patients, about 30% of patients do not respond to corticosteroids and require either an alternative...

  • Tacrolimus -- finally! Herrlinger, K. R.; Fellermann, K.; Stange, E. F. // Gut;Sep2006, Vol. 55 Issue 9, p1224 

    The article cites a study conducted by researcher H. Ogata and colleagues which examines the use of starlings in patients with refractory ulcerative colitis. The efficacy analysis included sixty patients of whom 15 were steroid resistant. High trough, low trough level and placebo groups achieved...

  • Tacrolimus.  // Reactions Weekly;6/8/2013, Issue 1456, p34 

    The article presents case studies of patients who developed de novo inflammatory bowel diseases while taking tacrolimus.

  • Tacrolimus Is Safe and Effective in Patients with Severe Steroid-Refractory or Steroid-Dependent Inflammatory Bowel Disease—A Long-Term Follow-Up. Baumgart, Daniel C.; Pintoffl, Jan P.; Sturm, Andreas; Wiedenmann, Bertram; Dignass, Axel U. // American Journal of Gastroenterology;May2006, Vol. 101 Issue 5, p1048 

    OBJECTIVE: We and others have reported the use of tacrolimus in refractory inflammatory bowel disease (IBD). Little is known about its long-term efficacy and safety. METHODS: In this retrospective, observational single center study the charts of 53 adult patients with steroid-dependent (n = 18)...

  • Management of acute severe colitis. Jakobovits, Simon L.; Travis, S. P. L. // British Medical Bulletin;Dec2005, Vol. 75/76 Issue 1, p131 

    The management of acute severe ulcerative colitis depends on early recognition of the unwell patient with colitis, the prompt initiation of treatment and objective assessment of the likelihood of medical failure. This deters ‘hopeful expectation’ in an attempt to avoid surgery....

  • Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Charpentier, Cloé; Salleron, Julia; Savoye, Guillaume; Fumery, Mathurin; Merle, Véronique; Laberenne, Jean-Eric; Vasseur, Francis; Dupas, Jean-Louis; Cortot, Antoine; Dauchet, Luc; Peyrin-Biroulet, Laurent; Lerebours, Eric; Colombe, Jean-Frédéric; Gower-Rousseau, Corinne // Gut;Mar2014, Vol. 63 Issue 3, p423 

    Data on the natural history of elderly-onset inflammatory bowel disease (IBD) are scarce. Methods In a French population-based cohort we identified 841 IBD patients >60 years of age at diagnosis from 1988 to 2006, including 367 Crohn's disease (CD) and 472 ulcerative colitis (UC). Results Median...

  • The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease. Naganuma, Makoto; Fujii, Toshimitsu; Watanabe, Mamoru // Journal of Gastroenterology;Feb2011, Vol. 46 Issue 2, p129 

    Background: Intravenous cyclosporine A (CsA) is an effective treatment for patients with severe, steroid-refractory ulcerative colitis (UC). Like the response to CsA, clinical trials have shown that two-thirds of patients with refractory UC respond to tacrolimus therapy. However, it is unclear...

  • Understanding the Use of Immunosuppressive Agents in the Clinical Management of IBD. Waters, O. R.; Lawrance, I. C. // Current Drug Targets;Aug2011, Vol. 12 Issue 9, p1364 

    No abstract available.

  • Meta-Analysis of the Placebo Response in Ulcerative Colitis. Sagar Garud; Alphonso Brown; Adam Cheifetz; Emily Levitan; Ciaran Kelly // Digestive Diseases & Sciences;Apr2008, Vol. 53 Issue 4, p875 

    Abstract   Purpose The placebo response rate in randomized controlled trials (RCTs) in ulcerative colitis (UC) varies from 0 to 76%. The aims of this study were to quantify the pooled placebo response rate and identify the factors affecting it. Methods We performed a...


Read the Article


Sign out of this library

Other Topics